A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

Not specified

Study Completion Date

September 30, 1996

Conditions
Sarcoma, KaposiHIV Infections
Interventions
DRUG

Bleomycin sulfate

DRUG

Vincristine sulfate

DRUG

Doxorubicin hydrochloride

DRUG

Zalcitabine

DRUG

Didanosine

Trial Locations (14)

10021

Memorial Sloan-Kettering Cancer Ctr., New York

14215

SUNY - Buffalo, Erie County Medical Ctr., Buffalo

27599

Unc Aids Crs, Chapel Hill

43210

The Ohio State Univ. AIDS CRS, Columbus

46202

Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis

60611

Northwestern University CRS, Chicago

80262

University of Colorado Hospital CRS, Aurora

90033

USC CRS, Los Angeles

90095

UCLA CARE Center CRS, Los Angeles

Unknown

Ucsf Aids Crs, San Francisco

Rush Univ. Med. Ctr. ACTG CRS, Chicago

Johns Hopkins Adult AIDS CRS, Baltimore

Washington U CRS, St Louis

02118

Bmc Actg Crs, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novum

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000954 - A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma | Biotech Hunter | Biotech Hunter